Low-density lipoprotein receptor-related protein 6 (LRP6) is a novel nutritional therapeutic target for hyperlipidemia, non-alcoholic fatty liver disease, and atherosclerosis

Nutrients

Volumn 7, Issue 6, 2015, Pages 4453-4464

  Go, Gwang Woong ^a  

^a Kookmin University   (South Korea)

Author keywords

Atherosclerosis; Dyslipidemia; LRP6; Non alcoholic fatty liver disease

Indexed keywords

ACYL COENZYME A DESATURASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR; TUBERIN; BETA CATENIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP6 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; B LYMPHOCYTE; BODY FAT; CELL DIFFERENTIATION; FIBROBLAST; GENE MUTATION; GLUCOSE METABOLISM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID HOMEOSTASIS; LIPOGENESIS; NONALCOHOLIC FATTY LIVER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; VASCULAR SMOOTH MUSCLE CELL; WNT SIGNALING PATHWAY; ANIMAL; BLOOD; DIET THERAPY; DISEASE MODEL; GENE TARGETING; GENETICS; HOMEOSTASIS; HUMAN; LIPID METABOLISM; METABOLISM; PROCEDURES;

ANIMALS; ATHEROSCLEROSIS; BETA CATENIN; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; GENE TARGETING; HOMEOSTASIS; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, LDL; TOR SERINE-THREONINE KINASES; TRIGLYCERIDES; WNT SIGNALING PATHWAY;

EID: 84930966066     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7064453     Document Type: Review

References (48)

1. Bilic, J.; Huang, Y.L.; Davidson, G.; Zimmermann, T.; Cruciat, C.M.; Bienz, M.; Niehrs, C. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science2007, 316, 1619–1622
2. Cselenyi, C.S.; Jernigan, K.K.; Tahinci, E.; Thorne, C.A.; Lee, L.A.; Lee, E. LRP6 transduces a canonical Wnt signal independently of axin degradation by inhibiting GSK3’s phosphorylation of beta-catenin. Proc. Natl. Acad. Sci. USA2008, 105, 8032–8037
3. Mani, A.; Radhakrishnan, J.; Wang, H.; Mani, A.; Mani, M.-A.; Nelson-Williams, C.; Carew, K.S.; Mane, S.; Najmabadi, H.; Wu, D.; et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315, 1278–1282
4. Lu, W.; Liu, C.-C.; Thottassery, J.V.; Bu, G.; Li, Y. MESD is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells. Biochemistry2010, 49, 4635–4643
5. Sladek, R.; Rocheleau, G.; Rung, J.; Dina, C.; Shen, L.; Serre, D.; Boutin, P.; Vincent, D.; Belisle, A.; Hadjadj, S.; et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445, 881–885
6. Perez-Martinez, P.; Perez-Caballero, A.I.; Garcia-Rios, A.; Yubero-Serrano, E.M.; Camargo, A.; Gomez-Luna, M.J.; Marin, C.; Gomez-Luna, P.; Dembinska-Kiec, A.; Rodriguez-Cantalejo, F.; et al. Effects of rs7903146 variation in the TCF7L2 gene in the lipid metabolism of three different populations. PLoS ONE 2012, 7, e43390
7. Muendlein, A.; Saely, C.H.; Geller-Rhomberg, S.; Sonderegger, G.; Rein, P.; Winder, T.; Beer, S.; Vonbank, A.; Drexel, H. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. PLoS ONE2011, 6, e17978
8. Tomaszewski, M.; Charchar, F.J.; Barnes, T.; Gawron-Kiszka, M.; Sedkowska, A.; Podolecka, E.; Kowalczyk, J.; Rathbone, W.; Kalarus, Z.; Grzeszczak, W.; et al. A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 1316–1321
9. Huertas-Vazquez, A.; Plaisier, C.; Weissglas-Volkov, D.; Sinsheimer, J.; Canizales-Quinteros, S.; Cruz-Bautista, I.; Nikkola, E.; Herrera-Hernandez, M.; Davila-Cervantes, A.; Tusie-Luna, T.; et al. TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia 2008, 51, 62–69
10. Sarzani, R.; Salvi, F.; Bordicchia, M.; Guerra, F.; Battistoni, I.; Pagliariccio, G.; Carbonari, L.; Dessì-Fulgheri, P.; Rappelli, A. Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. Nutr. Metab. Cardiovasc. Dis.2011, 21, 150–156
11. Liu, P.H.; Chang, Y.C.; Jiang, Y.D.; Chen, W.J.; Chang, T.J.; Kuo, S.S.; Lee, K.C.; Hsiao, P.C.; Chiu, K.C.; Chuang, L.M. Genetic variants of TCF7L2 are associated with insulin resistance and related metabolic phenotypes in taiwanese adolescents and caucasian young adults. J. Clin. Endocrinol. MeTable2009, 94, 3575–3582
12. Saxena, R.; Gianniny, L.; Burtt, N.P.; Lyssenko, V.; Giuducci, C.; Sjögren, M.; Florez, J.C.; Almgren, P.; Isomaa, B.; Orho-Melander, M.; et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55, 2890–2895
13. Wang, J.; Kuusisto, J.; Vänttinen, M.; Kuulasmaa, T.; Lindström, J.; Tuomilehto, J.; Uusitupa, M.; Laakso, M. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the finnish diabetes prevention study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia2007, 50, 1192–1200
14. Delgado-Lista, J.; Perez-Martinez, P.; García-Rios, A.; Phillips, C.M.; Williams, C.M.; Gulseth, H.L.; Helal, O.; Blaak, E.E.; Kiec-Wilk, B.; Basu, S.; et al. Pleiotropic effects of TCF7L2 gene variants and its modulation in the metabolic syndrome: From the lipgene study. Atherosclerosis 2011, 214, 110–116
15. Singh, R.; de Aguiar, R.B.; Naik, S.; Mani, S.; Ostadsharif, K.; Wencker, D.; Sotoudeh, M.; Malekzadeh, R.; Sherwin, R.S.; Mani, A. LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans. Cell MeTable2013, 17, 197–209
16. Keramati, A.R.; Singh, R.; Lin, A.; Faramarzi, S.; Ye, Z.-J.; Mane, S.; Tellides, G.; Lifton, R.P.; Mani, A. Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. USA2011, 108, 1914–1918
17. Ye, Z.J.; Go, G.W.; Singh, R.; Liu, W.Z.; Keramati, A.R.; Mani, A. LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake. J. Biol. Chem.2012, 287, 1335–1344
18. Cheng, Z.; Biechele, T.; Wei, Z.; Morrone, S.; Moon, R.T.; Wang, L.; Xu, W. Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nat. Struct. Mol. Biol.2011, 18, 1204–1210
19. Bryja, V.; Andersson, E.R.; Schambony, A.; Esner, M.; Bryjová, L.; Biris, K.K.; Hall, A.C.; Kraft, B.; Cajanek, L.; Yamaguchi, T.P.; et al. The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol. Biol. Cell 2009, 20, 924–936
20. Go, G.W.; Srivastava, R.; Hernandez-Ono, A.; Gang, G.; Smith, S.B.; Booth, C.J.; Ginsberg, H.N.; Mani, A. The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue. Cell MeTable2014, 19, 209–220
21. Liu, W.; Mani, S.; Davis, N.R.; Sarrafzadegan, N.; Kavathas, P.B.; Mani, A. Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. Circ. Res.2008, 103, 1280–1288
22. Register, T.C.; Hruska, K.A.; Divers, J.; Bowden, D.W.; Palmer, N.D.; Carr, J.J.; Wagenknecht, L.E.; Hightower, R.C.; Xu, J.; Smith, S.C.; et al. Plasma dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in african-americans with type 2 diabetes. J. Clin. Endocrinol. MeTable 2013, 98, E60–E65
23. Goliasch, G.; Wiesbauer, F.; Kastl, S.P.; Katsaros, K.M.; Blessberger, H.; Maurer, G.; Schillinger, M.; Huber, K.; Wojta, J.; Speidl, W.S. Premature myocardial infarction is associated with low serum levels of Wnt-1. Atherosclerosis2012, 222, 251–256
24. Morales-Santana, S.; García-Fontana, B.; García-Martín, A.; Rozas-Moreno, P.; García-Salcedo, J.A.; Reyes-García, R.; Muñoz-Torres, M. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care2013, 36, 1667–1674
25. Liu, W.; Singh, R.; Choi, C.S.; Lee, H.Y.; Keramati, A.R.; Samuel, V.T.; Lifton, R.P.; Shulman, G.I.; Mani, A. Low density lipoprotein (LDL) receptor-related protein 6 (LRP6) regulates body fat and glucose homeostasis by modulating nutrient sensing pathways and mitochondrial energy expenditure. J. Biol. Chem.2012, 287, 7213–7223
26. Ballantyne, C.; Arroll, B.; Shepherd, J. Lipids and CVD management: Towards a global consensus. Eur. Heart J. 2005, 26, 2224–2231
27. Aguilar-Salinas, C.; Gómez-Díaz, R.; Tusié-Luna, M.T. Fifty years studying hiperlipidemias: The case of familial combined hyperlipidemia. Invest. Clin.2010, 51, 145–158
28. Brown, M.S.; Goldstein, J.L. Familial hypercholesterolemia: Defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc. Natl. Acad. Sci. USA1974, 71, 788–792
29. Goldstein, J.L.; Brown, M.S.; Stone, N.J. Genetics of the LDL receptor: Evidence that the mutations affecting binding and internalization are allelic. Cell1977, 12, 629–641
30. Hobbs, H.H.; Brown, M.S.; Goldstein, J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat.1992, 1, 445–466
31. Ishibashi, S.; Brown, M.S.; Goldstein, J.L.; Gerard, R.D.; Hammer, R.E.; Herz, J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest.1993, 92, 883–893
32. Garcia, C.K.; Wilund K.; Arca M.; Zuliani G.; Fellin R.; Maioli M.; Calandra S.; Bertolini S.; Cossu F.; Grishin N.; Barnes R.; Cohen J.C.; Hobbs H.H. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science2001, 292, 1394–1398
33. Cohen, J.C.; Kiss, R.S.; Pertsemlidis, A.; Marcel, Y.L.; McPherson, R.; Hobbs, H.H. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science2004, 305, 869–872
34. Lifton, R.P.; Gharavi, A.G.; Geller, D.S. Molecular mechanisms of human hypertension. Cell 2001, 104, 545–556
35. Gwack, Y.; Sharma, S.; Nardone, J.; Tanasa, B.; Iuga, A.; Srikanth, S.; Okamura, H.; Bolton, D.; Feske, S.; Hogan, P.G.; et al. A genome-wide drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006, 441, 646–650
36. Bartz, F.; Kern, L.; Erz, D.; Zhu, M.; Gilbert, D.; Meinhof, T.; Wirkner, U.; Erfle, H.; Muckenthaler, M.; Pepperkok, R.; et al. Identification of cholesterol-regulating genes by targeted RNAi screening. Cell MeTable 2009, 10, 63–75
37. Wang, Y.; Shi, M.; Fu, H.; Xu, H.; Wei, J.; Wang, T.; Wang, X. Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease. Mol. Med. Rep.2010, 3, 909–915
38. Mauvoisin, D.; Rocque, G.; Arfa, O.; Radenne, A.; Boissier, P.; Mounier, C. Role of the PI3-kinase/mtor pathway in the regulation of the stearoyl coa desaturase (SCD1) gene expression by insulin in liver. J. Cell Commun. Signal2007, 1, 113–125
39. Miyazaki, M.; Flowers, M.T.; Sampath, H.; Chu, K.; Otzelberger, C.; Liu, X.; Ntambi, J.M. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell MeTable 2007, 6, 484–496
40. Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.L. TSC2 is phosphorylated and inhibited by AKT and suppresses mTOR signalling. Nat. Cell Biol.2002, 4, 648–657
41. Lamming, D.W.; Sabatini, D.M. A central role for mTOR in lipid homeostasis. Cell MeTable2013, 18, 465–469
42. Nakaya, H.; Summers, B.D.; Nicholson, A.C.; Gotto, A.M., Jr.; Hajjar, D.P.; Han, J. Atherosclerosis in Ldlr-knockout mice is inhibited, but not reversed, by the PPARγ ligand pioglitazone. Am. J. Pathol.2009, 174, 2007–2014
43. Jones, C.; Garuti, R.; Michaely, P.; Li, W.-P.; Maeda, N.; Cohen, J.C.; Herz, J.; Hobbs, H.H. Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J. Clin. Invest.2007, 117, 165–174
44. Plump, A.S.; Breslow, J.L. Apolipoprotein e and the apolipoprotein E-deficient mouse. Ann. Rev. Nutr.1995, 15, 495–518
45. Singh, R.; Smith, E.; Fathzadeh, M.; Liu, W.; Go, G.W.; Subrahmanyan, L.; Faramarzi, S.; McKenna, W.; Mani, A. Rare nonconservative LRP6 mutations are associated with metabolic syndrome. Hum. Mutat.2013, 34, 1221–1225
46. Keramati, A.R.; Fathzadeh, M.; Go, G.W.; Singh, R.; Choi, M.; Faramarzi, S.; Mane, S.; Kasaei, M.; Sarajzadeh-Fard, K.; Hwa, J.; et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N. Engl. J. Med. 2014, 370, 1909–1919
47. Zenibayashi, M.; Miyake, K.; Horikawa, Y.; Hirota, Y.; Teranishi, T.; Kouyama, K.; Sakaguchi, K.; Takeda, J.; Kasuga, M. Lack of association of LRP5 and LRP6 polymorphisms with type 2 diabetes mellitus in the japanese population. Endocr. J.2008, 55, 699–707
48. Srivastava, R.; Go, G.W.; Zhang J.; Mani, A. Loss of LRP6/TCF7L2 regulation of vascular smooth muscle cell phenotype contributes to coronary artery disease. Circulation2014, 130, A19224.